Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Moderna Hits a Short-Term Vaccine Manufacturing Delay, Still on Track for First 100 Million Doses by End of March


Moderna (NASDAQ: MRNA) has hit a bit of a snag with the manufacturing of its COVID-19 vaccine. The company's fill-and-finish contractor, Catalent (NYSE: CTLT), is experiencing delays with some of the doses it's responsible for getting out the door. The companies didn't disclose exactly what was causing the delay.

"Fill and finish" is the last step in the manufacturing process and involves putting the vaccine into vials, slapping on labels, and other steps needed to go from a large batch of vaccine product to something healthcare workers can use. It's a relatively straightforward process but is still highly regulated by the Food and Drug Administration and agencies from other countries.

Image source: Getty Images.

Continue reading


Source Fool.com

Like: 0
Share

Comments